Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 2/20 | 0.63 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.61 |
| ▸ | ITK | Q08881 | 10/20 | 0.56 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.53 |
| ▸ | FLT3 | P36888 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | MGLL | Q99685 | 1/20 | 0.51 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.50 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL145923 | 0.89 | KDR (0.62) | KDRCHEK1ITKMAPK10FLT3 | |
| SCHEMBL5952108 | 0.83 | FGFR1 (0.58) | KDRCHEK1ITKMAPK10FLT3 | |
| SCHEMBL13650123 | 0.82 | CHEK1 (0.51) | KDRCHEK1ITKFLT3MGLL | |
| SCHEMBL4125482 | 0.80 | ITK (0.81) | CHEK1ITK | |
| SCHEMBL5638192 | 0.79 | HRH4 (0.56) | KDRCHEK1ITKMAPK10HRH4 | |
| SCHEMBL1225812 | 0.79 | PDPK1 (0.61) | KDRCHEK1MAPK10FLT3HRH4 | |
| SCHEMBL31172237 | 0.79 | PDPK1 (0.61) | KDRCHEK1MAPK10FLT3HRH4 | |
| SCHEMBL146834 | 0.78 | CHEK1 (0.76) | CHEK1ITK | |
| SCHEMBL5078878 | 0.77 | KDR (1.00) | KDRCHEK1HPGDTSHRMGLL | |
| SCHEMBL12370825 | 0.77 | HRH4 (0.55) | KDRCHEK1ITKMAPK10FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7101884-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2006-09-05 | — | — | US | claimed |
| US-20050070546-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2005-03-31 | — | — | US | claimed |
| WO-2003024969-A1 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2003-03-27 | — | — | WO | claimed |
| US-20140221455-A1 | DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR | Verva Pharmaceuticals, Inc. (AU) | 2014-08-07 | — | — | US | disclosed |
| US-20120059047-A1 | DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR | VERVA PHARMACEUTICALS PTY LTD (AU) | 2012-03-08 | — | — | US | disclosed |
| US-7101884-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2006-09-05 | — | — | US | disclosed |
| US-20050282733-A1 | Differentiation modulating agents and uses therefor | VERVA PHARMACEUTICALS PTY LTD (AU) | 2005-12-22 | — | — | US | disclosed |
| WO-2005065686-A1 | DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR | ADIPOGEN PHARMACEUTICALS PTY LIMITED (AU) | 2005-07-21 | — | — | WO | disclosed |
| US-20050070546-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2005-03-31 | — | — | US | disclosed |
| WO-2003024969-A1 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2003-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059047-A1 | DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR | FGF1, FABP4, FGF2 | KDR 1077/4885CHEK1 3154/4885ITK 2496/4885 |
| US-20050070546-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | KDR 5/4885CHEK1 499/4885ITK 377/4885 |
| US-20050282733-A1 | Differentiation modulating agents and uses therefor | FGF1, FABP4, FGF2 | KDR 1077/4885CHEK1 3154/4885ITK 2496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.